Abstract
BackgroundThe response rate to immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) receptor is 13%–18% for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Detailed...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have